Literature DB >> 11473729

Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells.

Y Matsumoto1, H Takano, K Kunishio, S Nagao, T Fojo.   

Abstract

The cell lines described in the present study were isolated as part of an effort to understand resistance to topoisomerase (topo) II inhibitors. To that end, 50 sublines were isolated from four human breast cancer cell lines, i.e., MCF-7, T47D, MDA-MB-231, and ZR-75B. As an initial step, a concentration that would be lethal to the majority of cells (IC99) was selected for both VP-16 and mAMSA, for each cell line. The identification of an increasing number of putative drug resistance-related proteins provided the opportunity to examine expression of the corresponding genes in the selected cell lines. Northern blot analysis revealed different responses to the selecting agents in the different cell lines. Previous studies examining expression of multidrug resistance (MDR)-1 in resistant cell lines had found undetectable levels in all cells. In the ZR-75B sublines, increased expression of MDR-associated protein (MRP) and canalicular multispecific organic anion transporter (cMOAT) was observed, and when the relative levels of overexpression were compared, a high correlation was found. In contrast, increased expression of MRP was observed in some of the MDA-MB-231 sublines, without a concomitant increase in cMOAT expression. Finally, in both T47D and MCF-7 sublines, increased expression of cMOAT or MRP was observed infrequently, and where it occurred, was of a much smaller magnitude. In the analysis of expression of MRP, the highest levels were found in the ZR-75B and MDA-MB-231 sublines, with lower levels in the MCF-7 and T47D clones. Similarly, differences in the expression of topo IIalpha were observed among the sublines. Although the differences in expression appear to depend on the parental cell line from which the resistant sublines were derived, a strong correlation was observed between the expression of MRP and the levels of topo IIalpha. Cell lines with low levels of MRP had lower levels of topo IIalpha, while those with high levels of MRP maintained higher levels of topo IIalpha. While a reduced topo IIalpha level was common, there did not appear to be a compensating increase in the expression of topo IIbeta or topo I or casein kinase (CK) IIalpha in any of the cell lines. While the possibility that such compensation could occur has been discussed and even reported in some cell lines, such an adaptation was not observed in the present study, suggesting that it is not common.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11473729      PMCID: PMC5926780          DOI: 10.1111/j.1349-7006.2001.tb01161.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  35 in total

1.  Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.

Authors:  F H Drake; G A Hofmann; H F Bartus; M R Mattern; S T Crooke; C K Mirabelli
Journal:  Biochemistry       Date:  1989-10-03       Impact factor: 3.162

2.  Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression.

Authors:  J S Lee; S Scala; Y Matsumoto; B Dickstein; R Robey; Z Zhan; G Altenberg; S E Bates
Journal:  J Cell Biochem       Date:  1997-06-15       Impact factor: 4.429

3.  Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.

Authors:  S P Cole; E R Chanda; F P Dicke; J H Gerlach; S E Mirski
Journal:  Cancer Res       Date:  1991-07-01       Impact factor: 12.701

4.  Cell cycle phase-specific phosphorylation of human topoisomerase II alpha. Evidence of a role for protein kinase C.

Authors:  N J Wells; A M Fry; F Guano; C Norbury; I D Hickson
Journal:  J Biol Chem       Date:  1995-11-24       Impact factor: 5.157

5.  The regulation of DNA topoisomerase II by casein kinase II.

Authors:  G C Alghisi; E Roberts; M E Cardenas; S M Gasser
Journal:  Cell Mol Biol Res       Date:  1994

6.  Structure and mechanism of DNA topoisomerase II.

Authors:  J M Berger; S J Gamblin; S C Harrison; J C Wang
Journal:  Nature       Date:  1996-01-18       Impact factor: 49.962

Review 7.  DNA topoisomerase II as a target of antineoplastic drug therapy.

Authors:  L A Zwelling
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

8.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

9.  Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage.

Authors:  W Ross; T Rowe; B Glisson; J Yalowich; L Liu
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

10.  Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases.

Authors:  C A Austin; J H Sng; S Patel; L M Fisher
Journal:  Biochim Biophys Acta       Date:  1993-03-20
View more
  5 in total

1.  Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.

Authors:  Christian Borgo; Luca Cesaro; Valentina Salizzato; Maria Ruzzene; Maria Lina Massimino; Lorenzo A Pinna; Arianna Donella-Deana
Journal:  Mol Oncol       Date:  2013-08-22       Impact factor: 6.603

2.  Evaluation of (64)Cu(DO3A-xy-TPEP) as a potential PET radiotracer for monitoring tumor multidrug resistance.

Authors:  Shuang Liu; Young-Seung Kim; Shizhen Zhai; Jiyun Shi; Guihua Hou
Journal:  Bioconjug Chem       Date:  2009-04       Impact factor: 4.774

3.  Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.

Authors:  Valentina Salizzato; Christian Borgo; Luca Cesaro; Lorenzo A Pinna; Arianna Donella-Deana
Journal:  Oncotarget       Date:  2016-04-05

4.  Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines.

Authors:  Y Matsumoto; H Takano; K Kunishio; S Nagao; T Fojo
Journal:  Jpn J Cancer Res       Date:  2001-10

5.  Perturbation of the lipid phase of a membrane is not involved in the modulation of MRP1 transport activity by flavonoids.

Authors:  Olga Wesołowska; Andrzej B Hendrich; Barbara Łaniapietrzak; Jerzy Wiśniewski; Joseph Molnar; Imre Ocsovszki; Krystyna Michalak
Journal:  Cell Mol Biol Lett       Date:  2008-11-19       Impact factor: 5.787

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.